Lilly's Retevmo gains traditional approval in thyroid cancer

magicmine Eli Lilly's ( NYSE: LLY ) Retevmo (selpercatinib) has been granted traditional U.S. FDA approval for thyroid cancer in adults and pediatric patients two years and older.

The oncologic received accelerated approval for the indication, in RET fusion-positive thyroid cancer, in 2020 for patients 12 years and older. Efficacy was based on the LIBRETTO-001 trial which showed strong outcomes for overall response rate and duration of response. More on Eli Lilly Eli Lilly: The Road To Approval Of Donanemab Is Open Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs? GLP-1 obesity drug coverage dropped by Blue Cross Michigan: report Wall Street’s most overbought stocks include NVDA, COST, LLY, and others.